Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis

Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of neuroimmunology Ročník 271; číslo 1-2; s. 66 - 68
Hlavní autori: Brown, J. William L., Martin, Peter J., Thorpe, John W., Michell, Andrew W., Coles, Alasdair J., Cox, Amanda L., Vincent, Angela, Zandi, Michael S.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Netherlands Elsevier B.V 15.06.2014
Predmet:
ISSN:0165-5728, 1872-8421, 1872-8421
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.
Bibliografia:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0165-5728
1872-8421
1872-8421
DOI:10.1016/j.jneuroim.2014.03.012